Based on the Divi's Laboratories Limited stock forecast from 6 analysts, the average analyst target price for Divi's Laboratories Limited is INR 3,442.20 over the next 12 months. Divi's Laboratories Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Divi's Laboratories Limited is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Divi's Laboratories Limited’s stock price was INR 3,813.80. Divi's Laboratories Limited’s stock price has changed by +1.32% over the past week, +11.14% over the past month and +19.45% over the last year.
No recent analyst target price found for Divi's Laboratories Limited
No recent average analyst rating found for Divi's Laboratories Limited
Company Overview Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India. Address: Divi Towers, Hyderabad, India, 500032 Read Less
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufactur...Read More
Frequently Asked Questions About Divi's Laboratories Limited (DIVISLAB:NSE) Stock
Based on ratings from 6 analysts Divi's Laboratories Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, 2 sell and 3 hold ratings.
DIVISLAB:NSE stock's dividend yield is 0.80%.
Our analysis grades DIVISLAB:NSE stock's dividend yield at C. This means that DIVISLAB:NSE stock's dividend yield is above 74% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this DIVISLAB:NSE may be a average dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for DIVISLAB:NSE is INR 3,442.20 over the next 12 months. The maximum analyst target price is INR 3931 while the minimum anlayst target price is INR 3000.
DIVISLAB:NSE stock's Price/Earning ratio is 72.61.
Our analysis grades DIVISLAB:NSE stock's Price / Earning ratio at F. This means that DIVISLAB:NSE stock's Price/Earning ratio is above 80% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this DIVISLAB:NSE may be a overvalued for its sector.
The last closing price of DIVISLAB:NSE's stock was INR 3,813.80.
The most recent market capitalization for DIVISLAB:NSE is INR 1,014.45B.
Based on targets from 6 analysts, the average taret price for DIVISLAB:NSE is projected at INR 3,442.20 over the next 12 months.
This means that DIVISLAB:NSE's stock price may go down by -9.74% over the next 12 months.
We can't find any ETFs which contains Divi's Laboratories Limited's stock.
As per our most recent records Divi's Laboratories Limited has 8,433 Employees.
Divi's Laboratories Limited's registered address is Divi Towers, Hyderabad, India, 500032.
You can get more information about it from Divi's Laboratories Limited's website at https://www.divislabs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DIVISLAB:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
